Clementia Pharmaceuticals Inc (NASDAQ:CMTA) has coverage initiated with a Outperform rating

Analyst Ratings For Clementia Pharmaceuticals Inc (NASDAQ:CMTA)

Story continues below

Today, Robert W. Baird initiated coverage on Clementia Pharmaceuticals Inc (NASDAQ:CMTA) with a Outperform.

There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Clementia Pharmaceuticals Inc (NASDAQ:CMTA) is Buy with a consensus target price of $22.6667 per share, a potential 62.95% upside.

Some recent analyst ratings include

  • 1/18/2019-Clementia Pharmaceuticals Inc (NASDAQ:CMTA) has coverage initiated with a Outperform rating
  • 12/16/2018-Clementia Pharmaceuticals Inc (NASDAQ:CMTA) had its Buy rating reiterated by Bloom Burton
  • 8/10/2018-Clementia Pharmaceuticals Inc (NASDAQ:CMTA) had its Outperform rating reiterated by Wedbush with a $26.00 price target
  • 8/31/2017-Clementia Pharmaceuticals Inc (NASDAQ:CMTA) has coverage initiated with a Buy ➝ Buy rating and $32.00 price target
  • 8/28/2017-Clementia Pharmaceuticals Inc (NASDAQ:CMTA) has coverage initiated with a Outperform ➝ Outperform rating and $23.00 price target

    About Clementia Pharmaceuticals Inc (NASDAQ:CMTA)
    Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

    Recent Trading Activity for Clementia Pharmaceuticals Inc (NASDAQ:CMTA)
    Shares of Clementia Pharmaceuticals Inc closed the previous trading session at 13,91 +0,020 0,14 % with 14.05 shares trading hands.

    An ad to help with our costs